Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals

Lifeward Ltd. (NASDAQ: LFWD) has finalized a strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), enhancing its position as a diversified biomedical innovation company. The agreement includes the acquisition of Oramed's Protein Oral Delivery (POD™) technology and provides Lifeward access to up to $47 million in capital, with an initial $10 million accessed on March 25, 2026. Additionally, Lifeward has made changes to its board of directors as part of this transaction.